NCT04053881 (CIMREAL) is a clinical trial of Certolizumab pegol in Plaque Psoriasis, sponsored by UCB Biopharma SRL.

Who is sponsoring NCT04053881?

NCT04053881 is sponsored by UCB Biopharma SRL.

What drugs are being tested in NCT04053881?

Interventions in NCT04053881: Certolizumab pegol.

What condition does NCT04053881 study?

NCT04053881 studies Plaque Psoriasis.

Is NCT04053881 still recruiting?

NCT04053881 is currently completed. Last updated 23 January 2023.

Last reviewed 2023-01-23 · How we verify

NCT04053881: CIMREAL

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Assess How Well Certolizumab Pegol Works in Patients With Moderate to Severe Plaque Psoriasis as Part of Routine Clinical Practice

Completed Last updated 23 January 2023

What this trial tests

trial testing Certolizumab pegol in Plaque Psoriasis in 412 participants. Completed in 2 December 2022.

Timeline

21 August 2019

Primary endpoint
2 December 2022

2 December 2022

Quick facts

Lead sponsor	UCB Biopharma SRL
Status	Completed
Study type	OBSERVATIONAL
Enrollment	412
Start date	21 August 2019
Primary completion	2 December 2022
Estimated completion	2 December 2022
Sites	79 locations across France, Italy, Greece, Belgium, United Kingdom, Germany, Canada, Spain

Drugs / interventions tested

Certolizumab pegol (CERTOLIZUMAB PEGOL) — full drug profile →

Conditions studied

Plaque Psoriasis — all drugs for Plaque Psoriasis →

Sponsor

UCB Biopharma SRL — full company profile →

Who can join

18 and older, any sex, with Plaque Psoriasis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to assess the effectiveness of certolizumab pegol in patients with moderate to severe plaque psoriasis as part of routine clinical practice.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Certolizumab Pegol for the Treatment of Plaque Psoriasis in Routine Clinical Practice: One-Year Results from the CIMREAL Study.
Korge B, Vanhooteghem O, Lynde CW, Machovcova A, et al · · 2024 · cited 3× · PMID 38937404 · DOI 10.1007/s13555-024-01210-3

Verify or expand the search:

Other trials of Certolizumab pegol

Trials testing the same drug.

NCT04740814 — A Study to Assess the Pharmacokinetics of Certolizumab Pegol in Adults With Active Rheumatoid Arthritis · Phase 1 · completed
NCT04610476 — Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis · Phase 3 · unknown
NCT04123795 — A Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Children With Moderate to S · Phase 3 · active not recruiting
NCT03215277 — A Study to Test the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Patients With Active Ankylosing Spondyl · Phase 2 · completed
NCT02497976 — Pilot Study Evaluating the Efficacy of Certolizumab Pegol for Interstitial Cystitis · Phase 3 · completed

Other recruiting trials for Plaque Psoriasis

Currently open trials in the same condition.

NCT07357831 — A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psor · Phase 3 · recruiting
NCT07250802 — A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis · Phase 3 · recruiting
NCT06979453 — A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants Wit · Phase 3 · recruiting
NCT07234591 — A Study to Evaluate Effectiveness and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis · NA · recruiting
NCT07116967 — Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK) · Phase 3 · recruiting

Other UCB Biopharma SRL trials

Trials by the same sponsor.

NCT07465289 — A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gr · Phase 3 · not yet recruiting
NCT07463521 — A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis · Phase 3 · not yet recruiting
NCT07277660 — A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Stu · Phase 2 · recruiting
NCT07290036 — A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adu · Phase 1 · recruiting
NCT07286682 — A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UCB5285 in Healthy Study Participants · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04053881 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by UCB Biopharma SRL
Last refreshed: 23 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04053881.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing